Progenics Pharmaceuticals Inc (PGNX)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

ONE WORLD TRADE CENTER NEW YORK, NY 10007

Progenics Pharmaceuticals Inc focuses on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases.

Data as of 2019-12-02 11:40:29 -0500
Market Cap451.123 Million Shares Outstanding86.422 Million Avg 30-day Volume
P/E Ratio Dividend Yield EPS-0.845
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE Enterprise Value
Total Cash Current Debt Gross Profit
BETA 52-week High/Low6.31 / 3.42 Next Earnings Date Price to Cash FLow (P/CF)
Data provided by IEX Cloud
View SEC Filings from PGNX instead.

View recent insider trading info

Funds Holding PGNX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding PGNX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

CAMPBELL BRADLEY L

  • Director
No longer subject to file 2020-06-19 0

ENDE ERIC J

  • Director
No longer subject to file 2020-06-19 0

FERRANTE KAREN JEAN

  • Director
No longer subject to file 2020-06-19 0

WONG VIVIEN EVP, DEVELOPMENT

  • Officer
No longer subject to file 2020-06-19 0

TENBARGE BRYCE SVP, COMMERCIAL

  • Officer
No longer subject to file 2020-06-19 0

MACDOUGALL ANN L.

  • Director
No longer subject to file 2020-06-19 0

DAS ASHA CHIEF MEDICAL OFFICER

  • Officer
No longer subject to file 2020-06-19 0

OSORIO BENEDICT COO

  • Officer
No longer subject to file 2020-06-19 0

BER GERARD

  • Director
No longer subject to file 2020-06-19 0

MAEUSLI HEINZ CHRISTOPH

  • Director
No longer subject to file 2020-06-19 0

MIMS DAVID W. INTERIM CEO AND INTERIM CFO

  • Officer
  • Director
No longer subject to file 2020-06-19 0

FABBIO PATRICK CFO

0 2020-03-02 0

VELAN CAPITAL, L.P.

ALTIVA MANAGEMENT INC.

VENKATARAMAN BALAJI

  • 10% Owner
  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
8,011,733 2019-09-09 0

LTE PARTNERS, LLC

MELKONIAN CAPITAL MANAGEMENT, LLC

LTE MANAGEMENT, LLC

MELKONIAN RYAN

  • 10% Owner
  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
1,950,000 2019-09-05 0

NOHRIA VIRINDER

  • 10% Owner
  • SEE EXPLANATION OF RESPONSES
110,000 2019-08-22 0

SARPANGAL DEEPAK

  • 10% Owner
  • SEE EXPLANATION OF RESPONSES
0 2019-08-22 0

COOKE TERENCE

  • 10% Owner
  • SEE EXPLANATION OF RESPONSES
40,000 2019-08-22 0

KISHBAUCH MICHAEL D

0 2019-07-11 0

WILLIAMS NICOLE

0 2019-07-11 0

SCHEINBERG DAVID A

0 2019-07-11 0

CROWLEY PETER J

0 2019-07-11 0

BAKER MARK ROBERT CHIEF EXECUTIVE OFFICER

0 2019-03-01 0

SUMMER JEFFERY SVP, DIGITAL TECHNOLOGY

0 2018-03-01 0

BROADFIN HEALTHCARE MASTER FUND LTD

BROADFIN CAPITAL, LLC

KOTLER KEVIN

  • 10% Owner
No longer subject to file 2017-02-13 0

HIRT SHELDON EXECUTIVE VP & GENERAL COUNSEL

  • Officer
0 2016-03-01 0

ISRAEL ROBERT J EXECUTIVE VICE PRESIDENT, MEDI

  • Officer
35,050 2015-06-11 0

MADDON PAUL J

  • Director
0 2015-06-10 0

LOVALLO ANGELO WILLIAM JR VICE PRESIDENT FINANCE

  • Officer
0 2015-03-02 0

YOUSSOUFIAN HAGOP EXECUTIVE VICE PRESIDENT R&D

  • Officer
0 2014-03-03 0

GOFF STEPHEN P

  • Director
0 2013-06-12 0

OLSON WILLIAM C SENIOR VP, RESEARCH AND DEVELO

  • Officer
0 2013-04-04 0

BAKER CHARLES A

  • Director
0 2012-06-13 0

BRINER KURT W

  • Director
0 2012-06-13 0

MCKINNEY ROBERT A SENIOR VP, CFO

  • Officer
0 2012-03-01 0

DALTON MARK F

  • Director
0 2011-07-01 0

BOYD THOMAS A SR. VP, PRODUCT DEV.

  • Officer
47,137 2010-07-01 0

JACOBSON PAUL F

  • Director
125,600 2008-10-22 0

KREMER ALTON B VP, CLINICAL RESEARCH

  • Officer
25,302 2008-04-01 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
FundVantage Trust- Gotham Enhanced Index Plus Fund PGNX -12.0 shares, $-45.6 2020-03-31 N-PORT
FundVantage Trust- Gotham Index Plus All-Cap Fund PGNX -57.0 shares, $-216.6 2020-03-31 N-PORT

Elevate your investments